Faculty Opinions recommendation of HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection.

Author(s):  
Bjarte G Solheim
Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3104-3104 ◽  
Author(s):  
Cladd E. Stevens ◽  
Pablo Rubinstein ◽  
Andromachi Scaradavou

Abstract Background: Engraftment and survival in cord blood transplantation is affected by total nucleated cell (TNC) dose and HLA match grade. Thus, patients need assess to more cord blood units (CBUs) to provide for better matches and higher cell dose. Purpose: To examine the effect of HLA match grade and direction of mistmatch on outcome of cord blood transplantation with the aim to improve match algorithms and cord blood unit selection strategies. To apply the match algorithms in an empirical analysis of the chance of finding a CBU match by match grade, taking into account inventory size and donor ethnic background. Materials and Methods: Engraftment, GvHD, relapse, TRM and overall survival was evaluated in 1511 recipients of single CBU from the NYBC National Cord Blood Program transplanted through June 2005 (data available on 91% of eligible patients). The empirical chance of finding a full or 1 antigen mismatch (HLA-A, B at intermediate level and DRB1 at high resolution ) CBU was assessed for 14,378 patients on an inventory 25,917 CBUs from ethnically diverse donors (16.5% African-American, 17.0% Hispanic, 6.6% Asian, 50.4% Caucasian and 9.6% mixed). Results: HLA match grade correlated with engraftment, GvHD, relapse, TRM and overall survival, independent of the effect of TNC dose and other contributing factors. TNC dose/kg patient body weight (range 0.7 to >10.0 x 10^7/kg) did not affect outcome in fully matched CBU grafts. A two-fold increase in TNC dose, on average, was required to overcome differences in TRM and survival for 2 antigen mismatched grafts compared to 1 mismatch. Unidirectional mismatches in GvHD direction only (CBU homozygous at the mismatched loci) provided engraftment, TRM and survival rates that were the same as fully matched grafts, also with no apparent relationship to TNC dose. Patients with leukemia given CBU grafts with a GvHD only ismatch had a relapse rate that was the same at that of fully matched CBUs, whereas those with rejection only mismatches had a significantly higher relpase rate. In the empirical analysis of the chance of finding a match, including mismatch direction, 10.6% of patients could find a full match in an ethnically diverse CBU inventory. Including CBUs with 1 or 2 antigen mismatches only in the GvHD direction more than doubled the chance of finding a "good" match. The chance of finding a match or a CBU with 1 antigen mismatch correlated with patient ethnicity (patients had the best chance of finding a good match within their own ethnic group). African-American patients were the least likely of any group to find a suitable CBU (more than 5-fold less likely than Caucasions to find a full match), in part, because of their smaller numbers in the inventory and, in part, because of their greater HLA diversity. Increasing inventory size increased the chance of finding a full or 1 antigen matched CBU for all ethnic groups, but the improvement diminished progressively. Conclusions: HLA match level, including direction of mismatches, was associated with success of CBU transplantation. As with marrow donor registries, improvement in the probability of matching requires a progressively larger inventory size and depends on the donor ethnic diversity. Quantitatively larger number of donors are required for ethnic minority patients. Thus, the US National Cord Blood Inventory (planned for 150,000 new, high quality CBUs) should be enriched with ethnical diverse donors in order to meet the needs of ethnic minority patients who lack an HLA identical sibling donor.


Blood ◽  
2017 ◽  
Vol 130 (12) ◽  
pp. 1480-1482 ◽  
Author(s):  
Filippo Milano ◽  
Hilary Gammill ◽  
David C. Oliver ◽  
Sami B. Kanaan ◽  
J. Lee Nelson ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5796-5796
Author(s):  
Mary Berg ◽  
Jonathan A Gutman ◽  
Leslie Vinson ◽  
Nicole Draper

Abstract Background: Most adult patients are transplanted with two cord units to enhance engraftment after stem cell transplantation. Previous reports have demonstrated that one cord blood unit becomes dominant in the recipient and the other unit regresses. Complete chimerism with the dominant unit is achieved in >90% of patients by day +100 after transplantation. We report a case of a patient who initially demonstrated engraftment with one cord blood unit, but months later was found to be engrafted with the other unit. A 30 year old man underwent dual cord blood transplantation for Acute Myeloid Leukemia in June 2015. The cords had identical HLA types and were both 6/10 match to the patient. During his recovery, he experienced engraftment syndrome, mild sinusoidal obstruction syndrome, Enterococcus bacteremia, and prolonged count recovery. A bone marrow biopsy done on day +77 demonstrated no evidence of disease; chimerism studies demonstrated 95% donor cells (CD3: 44% cord 1, 56% cord 2; CD33: 100% cord 2; CD56: 16% cord 1, 84% cord 2, see table). He was noted to have converted his blood type from his original O-Positive to B-Positive. He returned to his home and was not seen at our institution for several months. When he returned for follow-up on day +244, he was found to have a blood type of A-Negative. Testing with a new specimen confirmed this finding. Chimerism studies were performed to evaluate the status of the two donors in his peripheral blood on day +306. Methods: A PCR-based STR assay was done on peripheral blood or bone marrow using the PromegaPowerPlex 16 HS System. The WBC populations were manipulated to create sub-populations enriched for CD3, CD33, and CD56, respectively. Results: No significant recipient DNA was found in any of the specimens. On day +29, Cord 1 dominated in the CD56 cell population, but Cord 2 dominated in the CD3 and CD33 populations. On day +77, Cord 2 dominated in all cell populations, but Cord 1 still represented nearly half (44%) of CD3 cells. On day +306, Cord 1 dominated all cell populations. Conclusion: The change in the patient's blood type is consistent with reversal of the dominance of the cord blood units received by this patient. Only one other case of this sort of reversal has been reported. This is not consistent with previously published data that the cord unit with higher CD3 chimerism as early as day +14 becomes the long-term engrafting unit. Table Table. Disclosures No relevant conflicts of interest to declare.


2012 ◽  
Vol 18 (7) ◽  
pp. 1108-1118 ◽  
Author(s):  
Antonia Moretta ◽  
Gabriella Andriolo ◽  
Daniela Lisini ◽  
Miryam Martinetti ◽  
Annamaria Pasi ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5166-5166 ◽  
Author(s):  
Shunro Kai ◽  
Mahito Misawa ◽  
Tohru Iseki ◽  
Satoshi Takahashi ◽  
Kenji Kishi ◽  
...  

Abstract Cord blood (CB) is being increasingly used as a source of hematopoietic stem cells for patients in need of stem cell transplantation when a HLA matched-related or unrelated donor is not found. However, cord blood transplantation (CBT) in adults is limited by its lower cell dose. We have started investigating whether transplant with two units of CB will make an engraftment faster and improve outcomes in adult patient lacking a suitable single CB unit. Four transplant centers have participated in this clinical study. Eligibility for this study are as follows; 1) high-risk or advanced hematological malignancy without a related donor, 2) no HLA-matched unrelated BM donor in JMDP or requirement for urgent transplantation, and 3) absence of single HLA 0–2 antigen-mismatched cord blood unit with a cell dose of >2.5x10e7/kg. Eleven patients with hematological malignancies (AML 7, MLL 2, ALL 1, LBL 1) were transplanted with two CB units, following myeloablative conditioning with fractionated TBI(12Gy)+ G-CSF (5?g/kg/dx2days) combined ara-C (12g/?) +CY (120mg/kg) or TBI(12Gy) + CY (120mg/kg). GVHD prophylaxis consisted of short term MTX and CSA. The median age was 33 years (range; 19–52) and median weight was 68kg (range 48– 84). CB grafts were HLA 0–2 antigen-mismatched to the patients and each other, with a median total cryopreserved cell dose of 3.88x10e7/kg (range; 2.83–4.79) and median CD34+ cell dose of 1.06x10e5/kg (0.62–2.6). Nine out of 11 patients engrafted successfully, and had 96–100% single donor chimerism at day+28 bone marrow aspirate. The median time to neutrophil engraftment (ANC >500 /?) was 21days (16–26) and median time to platelets >50000 /?was 53 days (32–98). Nine patients who survived more than 28 days had AGVHD (grade I in 2, II in 3, III in 1), and CGVHD (limited type) was developed in 4 of the 6 evaluable patients. Two patients died of sepsis at day 7 and 27 and one had relapse at day 249. Nine patients are now alive 3 to 16 months after CBT. These preliminary results suggest that multiple unit CBT seems to be useful for adult with hematological malignancies lacking an appropriate BM donor or a single CB unit. Further studies with double-unit CBT may be warranted.


Sign in / Sign up

Export Citation Format

Share Document